Key result
Heart transplantation significantly decreased elevated plasma levels of sRAGE and IGFBP7 in patients with end-stage heart failure to match healthy control levels, correlating with improved hemodynamics.
Why the study?
Metabolic derangement is implicated in the pathophysiology of HF and PH, motivating an evaluation of metabolic plasma protein dynamics linked to end-stage HF and associated PH relative to haemodynamics before and after HT.
Does heart transplantation normalize elevated plasma sRAGE and IGFBP7 levels and correlate with improved haemodynamics in patients with end-stage heart failure?
Cohort (n=46)
No
Does heart transplantation normalize elevated plasma sRAGE and IGFBP7 levels and correlate with improved haemodynamics in patients with end-stage heart failure?
Absolute Event Rate: 25% vs 61%
p-value: p=<0.0001
Plasma sRAGE and IGFBP7 are elevated in end-stage heart failure and normalize after heart transplantation, correlating with improvements in pulmonary haemodynamics.
sRAGE/IGFBP7 changes post-HT may track hemodynamic recovery in end-stage HF; leaves open biomarker utility pending prospective trials.
Aims Metabolic derangement is implicated in the pathophysiology of heart failure (HF) and pulmonary hypertension (PH). We aimed to identify the dynamics of metabolic plasma proteins linked to end-stage HF and associated PH in relation to haemodynamics, before and after heart transplantation (HT). Methods and results Twenty-one metabolic plasma proteins were analysed with proximity extension assay in 20 controls and 26 patients before and 1 year after HT. Right heart catheterizations were performed in the HF patients pre-operatively and 1 year after HT. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and insulin-like growth factor-binding protein 7 (IGFBP7) were higher in HF patients compared with controls (P < 0.0001) and decreased after HT (P < 0.0001), matching controls' levels. The decrease in sRAGE after HT correlated with improved mean pulmonary arterial pressure (rs = 0.7; P < 0.0001), pulmonary arterial wedge pressure (rs = 0.73; P < 0.0001), pulmonary vascular resistance (rs = 0.65; P = 0.00062), and pulmonary arterial compliance (rs = −0.52; P = 0.0074). The change in plasma IGFBP7 after HT correlated with improved mean right atrial pressure (rs = 0.71; P = 0.00011) and N-terminal pro-brain natriuretic peptide (rs = 0.71; P < 0.0001). Conclusions Our results indicate that plasma sRAGE may reflect passive pulmonary vascular congestion and the ‘mechanical’ state of the pulmonary vasculature in HF patients with or without related PH. Furthermore, sRAGE and IGFBP7 may provide additional insight into the pathophysiological mechanisms in HF and associated PH. Their potential clinical and therapeutic relevance in HF and associated PH need further investigation.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2020) conducted a cohort in Heart failure (n=46). Heart transplantation vs. Pre-transplantation was evaluated on Plasma levels of sRAGE (AU) (p=<0.0001). Heart transplantation significantly decreased elevated plasma levels of sRAGE and IGFBP7 in patients with end-stage heart failure to match healthy control levels, correlating with improved hemodynamics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: